BACE1 and Alzheimer disease: In our opinion, combining BACE1 serum measurement with other markers reflecting different coexistent pathological AD features (i.e. inflammation, vascular dysregulation, neurodegeneration) could be useful in multiple clinical contexts, including trial enrollment and monitoring.